Merck, Moderna declare Phase 3 success for personalized mRNA cancer vaccine

The next generation of immunotherapy appears to have arrived. Merck and Moderna on Wednesday said their personalized cancer vaccine, known as intismeran autogene, succeeded in its first Phase 3 trial that tested the program in ...